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Abstract
Background Right ventricular dysfunction (RVD) and cardiac
troponin I (cTnI) are important tools for risk stratification in
pulmonary embolism (PE). We investigate the association of
RVD and cTnI in normotensive PE patients and calculate a
cTnI cut-off level for predicting RVD and submassive PE.
Methods Cl in ica l , l abora to ry, rad io log ica l and
echocardiagraphic data were analysed. Patients were
categorised into groups with or without RVD and compared
focussing on cTnI. Effectiveness of cTnI for predicting RVD
and submassive PE was tested.
Results One hundred twenty-nine normotensive PE patients,
71 with and 58 without RVD, were included. Patients with
RVD were older (75.0 years (61.3/81.0) vs. 66.0 years (57.7/
75.1), P=0.019). cTnI (0.06 ng/ml (0.02/0.23) vs. 0.01 ng/ml
(0.00/0.03), P<0.0001) and D-dimer values (2.00 mg/l (1.08/
4.05) vs. 1.23 mg/l (0.76/2.26), P=0.016) were higher in PE
with RVD. cTnI was associated with RVD (OR 3.95; 95 % CI
1.95–8.02, p=0.00014). AUC for cTnI diagnosing RVD was
0.79, and for submassive PE0.87. Cut-off values for cTnI
predicting RVD and submassive PE were 0.01 ng/ml, with a
negative predictive value of 73 %. cTnI was positively corre-
lated with age, D-dimer and creatinine.
Conclusions In normotensive PE patients, cTnI is helpful for
risk stratification and excluding RVD. cTnI elevation is cor-
related with increasing age and reduced kidney function.
Keywords Pulmonary embolism . Thrombosis . Venous
thromboembolism . Cardiac troponin I . Tachycardia
Introduction
Acute pulmonary embolism (PE) is potentially life-
threatening [1–11]. Mortality from an acute PE event is close-
ly related to the initial haemodynamic status and cardiac
adaptation [1, 2, 4, 10, 12–17]. The diagnostic finding of right
ventricular dysfunction (RVD) or positive cardiac troponin
(cTn) levels in normotensive PE patients appears to alter the
patient’s prognosis significantly [1–4, 7–9, 11–14, 18–26].
We aimed to investigate the association of RVD and cardi-
ac troponin I (cTnI) in normotensive PE patients and the
potential cTnI for exclusion of RVD. Moreover, a further
objective was to investigate parameters that have an impact
on elevation of cTnI levels.
Patients and methods
We performed a retrospective analysis of normotensive pa-
tients with confirmed acute PE, who were treated in the
Internal Medicine Department of the St. Vincenz and Elisabeth
Hospital Mainz, Germany, between May 2006 and June 2011.
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Patients were identified by searching the hospital information
system database (ICD diagnostic code of PE: I26).
Enrolled subjects
Patients were eligible for our analysis if they had a confirmed
acute PE, were treated in the Internal Medicine Department of
the hospital, were haemodynamically stable (systolic blood
pressure ≥90 mmHg) according to the European Society of
Cardiology (ESC) guidelines [4] and American Heart Associ-
ation (AHA) scientific statement [21], an accurate transthoracic
echocardiography (TTE) of acute phase was assessed and pa-
tients were at least 18 years of age. Diagnosis of acute PE was
confirmed by an identified filling defect in the pulmonary artery
system in a computed tomography pulmonary angiogram of the
chest (CT) or positive venous ultrasound/phlebography of an
extremity consistent with deep vein thrombosis (DVT) in pa-
tients with typical symptoms of PE (chest pain or dyspnoea)
and a detected positive D-dimer or scintigraphic ventilation-
perfusion (V/Q) scan read as high probability for PE. If the
diagnosis of PE was not confirmed or the criteria mentioned
above were not fulfilled, patients were not included in this
analysis. Studies with retrospective analysis of diagnostic stan-
dard data do not need an ethics statement in Germany.
Analysed data
Retrospectively analysed data comprised symptoms, medical
history, physical examination, laboratory parameters (cTnI,
creatine kinase (CK), creatinine, D-dimer), complications
and examination results.
Definitions
Per definition, cTnI values were elevated if they exceeded
0.1 ng/ml, and D-dimer values if they exceeded 0.110 mg/l.
RVD in TTE was defined according to the ESC guidelines
[4] and AHA scientific statement [21] as abnormal motion
of the interventricular septum, right ventricular (RV)
hypokinesis, pressure overload with tricuspid valve insuf-
ficiency or RV enlargement (quotient of end-diastolic lat-
eral-septal RV diameter/end-diastolicleft ventricular
lateral-septal diameter>0.9, referring to AHA scientific
statement [21]).
According to the ESC guidelines [4] and AHA scientific
statement [21] the PE patients of our study with RVD or
pathological cTnI levels were classified as submassive PE
with an intermediate risk and those without both were classi-
fied as low-risk PE.
Fig. 1 Cardiac troponin I level in
PE patients with and without
RVD
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Study groups
According to TTE results the normotensive PE patients were
included in one of the two study groups: the PE group with
RVD or the PE group without RVD.
Statistical analysis
We compared the groups especially focussing on cTnI. Effec-
tiveness of cTnI to predict RVD was tested. Continuous
distributed variables were described by median and interquar-
tile range and tested with the Mann–Whitney U-test if they
were not normally distributed or by mean, standard deviation
(SD) and tested with the Student t-test if distribution was
normal. Discrete variables were compared with the Chi-
square test. A value of P<0.05 was considered to be statisti-
cally significant.
Receiver operating characteristic (ROC) curve and Youden
index were calculated to test the effectiveness of cTnI to
predict RVD as well as cTnI to predict submassive PE. Mul-
tivariate regression analysis was performed to test coherence
of cTnI, gender, age, CK, creatinine, and D-dimer on RVD.
Spearman’s rank correlation was calculated for age, cTnI, CK,
creatinine, D-dimer, systolic blood pressure, diastolic blood
pressure, heart rate and systolic pulmonary artery pressure
(sPAP).
R version 2.14.1 from R Development Core Team (2011)
(R Foundation for Statistical Computing, Vienna, Austria)
was used for data processing.
Table 1 Characteristics of normotensive PE patients with and without RVD
PE without RVD (n=58) PE with RVD (n=77) p-value
Sex (women) 58.6 % (34) 60.6 % (43) 0.97
Age (years) 66.0 (57.7/75.1) 75.0 (61.3/81.0) 0.019
Comorbidities
Surgery or trauma in last 3 months before PE event 24.1 % (14) 14.1 % (10) 0.22
DVT or PE in patient’s history 24.6 % (14) 25.4 % (18) 0.92
DVT 72.4 % (42) 69.0 % (49) 0.82
Lung infarction with pneumonia 31.0 % (18) 52.1 % (37) 0.026
In-hospital death 0 % (0) 1.4 % (1) 0.92
Symptoms
Chest pain 34.5 % (20) 32.4 % (23) 0.95
Dyspnoea 84.5 % (49) 85.9 % (61) 0.98
Haemoptysis 3.4 % (2) 4.2 % (3) 0.82
Syncope or collapse 5.2 % (3) 14.1 % (10) 0.17
Tachycardia 20.7 % (12) 52.1 % (37) 0.00051
Physical examination
Systolic blood pressure (mmHg) 151.4±23.5 143.6±24.8 0.070
Diastolic blood pressure (mmHg) 80.9±20.4 79.5±15.3 0.65
Heart rate (beats/min) 80.5 (70.0/97.2) 100.0 (85.3/108.0) < 0.0001
ECG
Incomplete or complete RBBB 3.5 % (2) 19.7 % (14) 0.013
S1Q3type 3.5 % (2) 14.1 % (10) 0.083
Laboratory
Cardiac troponin I (ng/ml) 0.01 (0/0.03) 0.06 (0.02/0.23) < 0.0001
Creatine kinase (U/l) 62.0 (44.0/87.0) 65.0 (41.0/105.3) 0.71
Creatinine (mg/dl) 1.00 (0.80/1.11) 1.10 (0.90/1.38) 0.0062
D-dimer (mg/l) 1.23 (0.76/2.26) 2.00 (1.08/4.05) 0.016
Echocardiography
Systolic PA pressure (mmHg) 22.79±14.89 43.00±16.06 < 0.0001
Submassive PE stage (= existing RVD or elivated cTnI levels (>0.1 ng/ml)) 10.3 % (6) 100 % (77) < 0.0001
Continuous variables are described by median, 25th and 75th percentile, if they had a skewed distribution (|skewness| >1). Nearly normally distributed
variables are presented as mean values and standard deviation. Discrete variables are described through relative and absolute frequencies. Discrete
variables were tested with the Chi-square test for contingency tables; continuous variables were analysed with Student’s T Test if they were normally
distributed the Mann–Whitney-U test on skewed distribution
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Results
Altogether, 182 patients with acute and confirmed PE were
identified in the hospital information system database, but
only 129 patients met the criteria of inclusion; 77 women
and 52 men with normotensive PE were included in this
analysis. The diagnosis of PE was confirmed in 84.4 % by
CT,10.1 % by V/Q scan and 5.5 % by DVT diagnosis in
ultrasound/phlebography with typical symptoms of PE and
positive D-dimer.
While 45.0% of the PE patients did not showRVD in TTE,
55.0 % had RVD criteria. Patients with RVD were older
(75.0 years (61.3/81.0) vs. 66.0 years (57.7/75.1), P=0.019),
showed higher levels of heart rate (100.0 beats/min (85.3/
108.0) vs. 80.5 beats/min (70.0/97.2), P<0.0001), sPAP
(43.00±16.06 mmHg vs. 22.79±14.89 mmHg, P<0.0001),
cTnI (0.06 ng/ml (0.02/0.23) vs. 0.01 ng/ml (0.00/0.03),
P<0.0001) (Fig. 1), D-dimer (2.00 mg/l (1.08/4.05) vs.
1.23 mg/l (0.76/2.26), P=0.016) and creatinine (1.10 mg/dl
(0.90/1.38) vs. 1.00 mg/dl (0.80/1.11), P=0.0062), more fre-
quently had a lung infarction with pneumonia (52.1 vs.
31.0%, P=0.026) and an incomplete or complete right bundle
branch block (RBBB) (19.7 vs. 3.5 %, P=0.013) (Table 1).
cTnI was not higher in PE patients >65 years than in those
≤65 years (0.03 ng/ml (0.01/0.16) vs. 0.02 (0.00/0.08), P=
0.10). In the PE group without RVD, 10.3 % of patients
showed positive cTnI values. Of the 129 PE patients, 52 were
classified as low-risk PE and 77 as submassive PE (Table 1).
Analysis of the ROC curve showed an AUC of 0.79 for
cTnI predicting RVD with an optimal cut-off value of
0.01 ng/ml. Of the normotensive PE patients, 58.6 % had
cTnI values above 0.01 ng/ml. Sensitivity was 80 % (95 %
CI 68–89 %), specificity 67 % (95 % CI 53–80 %), positive
predictive value (PPV) 75% (95 % CI 63–85%) and negative
predictive value (NPV) 73 % (95 % CI 58–85 %). AUC value
and cTnI cut-off value predicting RVD as well as sensitivity,
specificity, positive and negative predictive value have
already been published in another context [24]. We have
quoted these results once again to complete the general
view on this topic.
Analysis of the ROC curve revealed an AUC of 0.87 for
cTnI predicting submassive PE with an optimal cut-off value
of 0.01 ng/ml (Fig. 2). Sensitivity was calculated as 81 %
(95%CI 70–90%), specificity 76% (95%CI 61–87%), PPV
84 % (95 % CI 73–92 %) and NPV 73 % (95 % CI 58–85 %).
In multivariable logistic regression a strong association be-
tween cTnI and RVDwas proven (OR 3.95; 95%CI 1.95–8.02,
p=0.00014) (Table 2). Spearman’s rank correlation showed a
positive correlation between cTnI and D-dimer (r=0.33), sPAP
(r=0.32) and creatinine (r=0.31), respectively (Fig. 3).
Fig. 2 Receiver operating
characteristic (ROC) curve with
area under the curve (AUC) for
effectiveness of cardiac troponin I
to predict submassive PE with
intermediate risk
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Discussion
Echocardiography, CT and cardiac biomarkers, particularly
cTn, are important tools for risk stratification in normotensive
PE patients. In acute PE, presence of RVD or elevated cTn
levels is associated with increased mortality [1, 2, 4, 7, 9, 10,
12–16, 18–22, 27–31].
Our study confirms a strong association between
cTnI and RVD in normotensive PE patients. The cal-
culated OR of 3.95 is in accordance with the literature
[27, 32, 33]. AUC for cTnI predicting RVD was 0.79,
which is similar to published AUC values of other
studies [34, 35].
We calculated a cut-off value of 0.01 ng/ml for cTnI
predicting RVD [24], which is in concordance with
other study results [34]. Sensitivity, specificity, PPV
and NPV were similar to other studies [34] and espe-
cially the PPV and NPV were high [24]. These results
of AUC, cut-off value, sensitivity, specificity, PPV and
NPV were previously published in an investigation for
the comparison of three variations of RVD definitions
[24]. But, in our opinion, these data are important to
complete the general view on this topic and we have
therefore quoted them once again.
Only 10.3 % of the PE patients without RVD showed an
elevated cTnI value. These patients had myocardial damage
without detected RVD and therefore were also categorised as
submassive PE with intermediate risk.
At a first glance, calculation of an AUC for cTnI
predicting the submassive stage of PE seems to make no
sense. But, after careful consideration this calculated AUC
could be used to evaluate the importance of the parameter
cTnI for assessment of submassive PE. Especially the small
difference between the AUC of cTnI predicting RVD and
Fig. 3 Spearman’s rank
correlation coefficient for several
parameters
Table 2 Multivariate logistic regression to detect the coherence of
RVD and cTnI and other parameters
OR (95 % CI) p-value
Gender 0.721 (0.263–1.977) 0.52
Age 1.199 (0.715–2.011) 0.49
Log (cardiac troponin I) 3.954 (1.949–8.024) 0.00014
CK 1.843 (0.287–11.822) 0.52
Creatinine 1.331 (0.721–2.457) 0.36
D-dimer 0.964 (0.588–1.581) 0.88
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cTnI predicting submassive PE seems to indicate that in our
analysis RVD was quite a lot more important for the
classification of submassive PE than cTnI. The consistent
cut-off values of cTnI for prediction of RVD and
submassive PE indicate that the cTnI value to differentiate
between normal and pathological is too high. A lower
cut-off value for the definition of pathological findings
and especially for defining the submassive stage of PE
should be chosen in the future.
In a previous investigation, in 179 PE patients of the
identified 182 PE patients, we analysed the association of
cTnI for risk stratification in haemodynamically unstable
and normotensive PE patients together [36]. In the larger
analysed group of PE patients, RVD diagnosis was made not
only by TTE, but also byCT. In 3 of the 182 patients RVDwas
not detectable and these 3 patients were therefore not
included in the analysis [36]. In these 179 PE patients
the association between cTnI and RVD was similar to
the present analysis (OR 3.98) [36]. AUC for cTnI
predicting RVD was 0.81 with a cut-off level of
0.01 ng/ml [36]. Increasing age, reduced kidney func-
tion and higher activation of coagulation system are
connected with elevated cTnI values.
In all patients with an acute PE event, anticoagulation
therapy is recommended with the aim to prevent early
death and to avoid symptomatic recurrent VTE, espe-
cially fatal PE [31]. Thrombolytic treatment is not the
standard treatment regime in normotensive PE patients,
but could be considered if signs of haemodynamic de-
compensation appear [31]. In the 129 normotensive PE
patients of our study we started anticoagulation treat-
ment, but thrombolytic treatment was not given in any
of these patients.
Limitations and strength
Limitations of this study are the small number of included
patients and the retrospective character. With these data, we
were not able to draw conclusions about follow-up outcome.
Despite these limitations we were able to find answers to the
main questions of the analysis.
Conclusions
In normotensive PE patients, cTnI is helpful for risk stratifi-
cation and especially for exclusion of RVD. Increasing age,
reduced kidney function and higher activation of coagulation
system are connected with elevated cTnI values.
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